PAVmed Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
PAVM$1.63+3.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands except number of shares and per share data)
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | $2,995 | $2,452 |
| Operating expenses: | ||
| Cost of revenue | 4,840 | 6,420 |
| Sales and marketing | 11,627 | 17,583 |
| General and administrative | 24,524 | 30,947 |
| Amortization of acquired intangible assets | 559 | 2,021 |
| Research and development | 5,932 | 14,276 |
| Total operating expenses | 47,482 | 71,247 |
| Operating loss | (44,487) | (68,795) |
| Other income (expense): | ||
| Interest income | 254 | 505 |
| Interest expense | (45) | (589) |
| Gain on deconsolidation of subsidiary | 72,287 | — |
| Change in fair value - equity method investment | 532 | — |
| Change in fair value - Senior Secured Convertible Notes | 462 | (6,026) |
| Loss on issue and offering costs - Senior Secured Convertible Note | — | (1,186) |
| Debt extinguishments loss - Senior Secured Convertible Notes | (2,535) | (3,782) |
| Debt modification expense | (2,000) | — |
| Change in fair value - derivative liability | — | (390) |
| Management fee income | 3,850 | — |
| Grant income | 109 | — |
| Gain on sale of intellectual property | — | 1,000 |
| Other income (expense), net | 72,914 | (10,468) |
| Income (loss) before provision for income tax | 28,427 | (79,263) |
| Provision for income taxes | — | — |
| Net income (loss) before noncontrolling interests | 28,427 | (79,263) |
| Net loss attributable to the noncontrolling interests | 11,364 | 15,088 |
| Net income (loss) attributable to PAVmed Inc. | 39,791 | (64,175) |
| Less: Deemed dividend on Series Z warrant modification | — | (1,791) |
| Less: Series B Convertible Preferred Stock dividends earned | (329) | (304) |
| Less: Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests | (7,496) | — |
| Net income (loss) attributable to PAVmed Inc. common stockholders | $31,966 | $(66,270) |
| Per share information: | ||
| Net income (loss) per share attributable to PAVmed Inc. common stockholders – basic | $3.30 | $(9.16) |
| Net income (loss) per share attributable to PAVmed Inc. common stockholders – diluted | $0.50 | $(9.16) |
| Weighted average common shares outstanding, basic | 9,672,199 | 7,231,546 |
| Weighted average common shares outstanding, diluted | 65,291,623 | 7,231,546 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.